ClinicalTrials.gg
Not yet recruitingNCT07942584PROST-3Updated Nov 17, 2026

Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of Onset

A Phase 3 interventional study of Recombinant Human Prourokinase for Injection (rhPro-UK) and Aspirin Enteric-Coated Tablets in Acute Ischemic Stroke AIS, sponsored by Tasly Biopharmaceuticals Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Tasly Biopharmaceuticals Co., Ltd. (part of China Resources Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
978
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 751 studies in Ischemic Stroke with a site in China — 378 open to participants now, 397 under way, 77 of them phase 3. Ischemic Stroke · China.

Planned enrollment
108th of 564
978 · median 268
Started
2026
with 122 others
Phase 3
110 of 751
64 open now
Primary completion
2029-03
later than 359 of 396 live
Registered
751st of 751
by date

Among the 751 studies in Ischemic Stroke with a site in China, this one is the 108th largest by planned enrollment of the 564 interventional ones that give a count, is one of 123 that started in 2026, is one of 110 in phase 3, reaches primary completion later than 359 of the 396 other live ones, and was the 751st registered.

Ischemic Stroke

2,623 studies on the registry are indexed under Ischemic Stroke; 981 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

378 of the 751 studies in Ischemic Stroke with a site in China are open now. Recruiting first, the newest first:

373 more — sign in →

All 378 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 665 Ischemic Stroke studies recruiting now, 399 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 751 studies in Ischemic Stroke with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, double-dummy, standard-of-care-controlled Phase III clinical trial to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in adult patients with acute ischemic stroke (AIS) within 4.5 to 24 hours of symptom onset, including wake-up stroke and unwitnessed stroke.Eligible patients with salvageable ischemic tissue confirmed by CT perfusion or MRI perfusion/diffusion imaging will be randomized in a 1:1 ratio to receive either intravenous rhPro-UK 35 mg plus oral aspirin enteric-coated tablet placebo, or intravenous rhPro-UK placebo plus oral aspirin enteric-coated tablets 100-300 mg (standard of care).The primary objective is to evaluate the efficacy of intravenous rhPro-UK compared with standard of care in achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. A total of 978 participants (489 per arm) will be enrolled at multiple centers in China.

Read the detailed description

Study Design: This is a multicenter, randomized, double-blind, double-dummy, standard-of-care (SOC)-controlled Phase III trial conducted at multiple centers in China. Randomization is performed using a stratified block randomization method, stratified by planned mechanical thrombectomy (2 levels: yes; no), with participants assigned in a 1:1 ratio to the rhPro-UK group or the SOC group.Treatment: Eligible and randomized participants receive the assigned investigational product as soon as possible (actual treatment initiation must be >4.5 hours and \<=24 hours after stroke onset). The rhPro-UK group receives an intravenous infusion of rhPro-UK 35 mg in normal saline (15 mg as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg by intravenous infusion/pump over 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg at the start of thrombolysis. The SOC group receives an intravenous infusion of rhPro-UK placebo (same regimen) plus oral aspirin enteric-coated tablets 100-300 mg. All investigational products are administered once only; subsequent clinical antiplatelet therapy should be initiated no earlier than 24 hours after completion of the investigational product administration.Study Duration: The total duration of participation for each participant is approximately 90 days, including a screening period (pre-thrombolysis, -24 hours to 0 hour), a treatment period (thrombolysis, 0 hour), and a follow-up period (24 hours, 72 hours, Day 7, Day 30, and Day 90 after the start of thrombolysis).Statistical Considerations: The study hypothesis is based on the primary estimand. Null hypothesis H0: p1/p2 \<= 1; alternative hypothesis H1: p1/p2 > 1, where p1 is the proportion of participants with an mRS score of 0-1 at 90 days in the rhPro-UK group and p2 is that in the SOC group. One interim analysis is planned, using the Lan-DeMets spending function with O'Brien-Fleming efficacy boundaries; the two-sided type I error is controlled at 0.003 for the interim analysis and 0.049 for the final analysis, maintaining an overall two-sided type I error of 0.05.Committees: An Academic Committee will be established before trial initiation to ensure the scientific feasibility of the protocol and standardization of trial conduct. An independent Clinical Events Committee (CEC) will adjudicate the type and drug-relatedness of all-cause death events within 7 days after treatment, as well as symptomatic intracranial hemorrhage (sICH). A Data Monitoring Committee (DMC) will convene regularly or as needed to perform unblinded sample size re-estimation, review safety data, and advise the sponsor on whether to continue, suspend, or stop the trial, or adjust the sample size.

03

Conditions studied

  • Acute Ischemic Stroke AIS

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age >=18 years, male or female;
  2. Time from stroke symptom onset to planned thrombolysis >4.5 hours and \<=24 hours (including wake-up stroke and unwitnessed stroke); the time of symptom onset is defined as the time the patient was last known to be well;
  3. Proximal or distal occlusion/stenosis of the internal carotid artery, middle cerebral artery, anterior cerebral artery, or posterior cerebral artery confirmed by CTA or MRA, identified as the culprit vessel responsible for the current acute ischemic stroke;
  4. Salvageable ischemic tissue demonstrated on CT perfusion (CTP) or MRI PWI/DWI sequences (infarct core volume \<70 mL; hypoperfusion-to-infarct core mismatch ratio >=1.8; mismatch volume >=15 mL);
  5. NIHSS score of 6 to 25 (inclusive);
  6. Pre-stroke mRS score \<2;
  7. No significant improvement in stroke clinical manifestations before treatment (as assessed by the investigator);
  8. The patient or his/her legally authorized representative is willing to participate in the trial and agrees to sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Unable to complete CTP/CTA or PWI/DWI/MRA examination;
  2. Large cerebral infarction indicated by CT/MRI (infarct area larger than one-third of the middle cerebral artery territory);
  3. Intracranial hemorrhage shown on CT/MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/epidural hematoma, etc.);
  4. Previous history of intracranial hemorrhage;
  5. Major head trauma or ischemic stroke within the past 3 months;
  6. Intracranial tumor or giant intracranial aneurysm;
  7. Intracranial or intraspinal surgery within the past 3 months;
  8. Gastrointestinal or urinary tract bleeding within the past 3 weeks;
  9. Major surgery or severe trauma within the past 2 weeks (as assessed by the investigator);
  10. Arterial puncture at a non-compressible site within the past 1 week;
  11. Active internal bleeding;
  12. Aortic arch dissection;
  13. Bacterial endocarditis or pericarditis;
  14. Hypertension remaining uncontrolled despite active antihypertensive therapy, with a post-treatment systolic blood pressure still >185 mmHg or diastolic blood pressure still >110 mmHg;
  15. Acute bleeding tendency, including count \<100 x 10\^9/L;
  16. Treatment with low-molecular-weight heparin or heparin within 24 hours;
  17. Use of thrombin inhibitors or factor Xa inhibitors within the past 48 hours;
  18. Currently taking oral anticoagulants with (PT) >15 seconds or international normalized ratio (INR) >1.7;
  19. Seizure at stroke onset, or coexisting psychiatric disorder precluding compliance;
  20. Blood glucose \<2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL);
  21. Severe hepatic insufficiency, including liver failure, cirrhosis, portal hypertension (esophageal varices), or active hepatitis;
  22. Severe renal insufficiency ( \<30 mL/min/1.73 m\^2);
  23. Any terminal illness with a of less than 1 year;
  24. Known to rhPro-UK, the active ingredient of aspirin, or any other components of the products;
  25. Pregnant or lactating women;
  26. Participation in another clinical trial within the past 1 month;
  27. Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the trial;
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
978 participants (estimated)

Study arms

  • Experimental
    rhPro-UK Group

    Participants receive an intravenous infusion of recombinant human prourokinase (rhPro-UK) 35 mg in normal saline (15 mg administered as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg administered by intravenous infusion/pump over the subsequent 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.

    Drug: Recombinant Human Prourokinase for Injection (rhPro-UK) · Drug: Aspirin Enteric-Coated Tablet Placebo

  • Active comparator
    Standard of Care (SOC) Group

    Participants receive an intravenous infusion of rhPro-UK placebo in normal saline (same administration regimen as the rhPro-UK group), plus oral aspirin enteric-coated tablets 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.

    Drug: Aspirin Enteric-Coated Tablets · Drug: rhPro-UK Placebo

Interventions

  • DrugRecombinant Human Prourokinase for Injection (rhPro-UK)

    rhPro-UK 35 mg dissolved in normal saline, administered intravenously as a single dose: 15 mg slow intravenous bolus over 3 minutes, followed by 20 mg intravenous infusion/pump over 30 minutes. Treatment initiation must be \>4.5 hours and \<=24 hours after stroke onset.

  • DrugAspirin Enteric-Coated Tablets

    Oral aspirin enteric-coated tablets 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion). Subsequent clinical antiplatelet therapy is initiated no earlier than 24 hours after completion of the investigational product administration.

  • DrugAspirin Enteric-Coated Tablet Placebo

    Oral placebo matching aspirin enteric-coated tablets, 100-300 mg, administered once at the start of thrombolysis (dose at the investigator's discretion).

  • DrugrhPro-UK Placebo

    Placebo matching rhPro-UK for injection, dissolved in normal saline and administered intravenously with the same regimen as rhPro-UK (15 mg-equivalent slow intravenous bolus over 3 minutes, followed by 20 mg-equivalent intravenous infusion/pump over 30 minutes), single dose.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Achieving a Favorable Functional Outcome (mRS 0-1)

    Description: Proportion of participants with a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment.

    Time frame: 90 days after treatment

Secondary outcomes

  1. Distribution of mRS Scores

    Distribution of modified Rankin Scale (mRS) scores at 90 days after treatment

    Time frame: 90 days after treatment

  2. Proportion of Participants Achieving Functional Independence (mRS 0-2)

    Proportion of participants with an mRS score of 0-2 at 90 days after treatment.

    Time frame: 90 days after treatment

  3. Proportion of Participants With Early Neurological Improvement at 24 Hours

    Proportion of participants with a decrease of \>=4 points in the National Institutes of Health Stroke Scale (NIHSS) score from baseline, or an NIHSS score \<=1, at 24 hours after treatment.

    Time frame: 24 hours after treatment

  4. Proportion of Participants With Neurological Improvement at Day 7

    Proportion of participants with a decrease of \>=4 points in NIHSS score from baseline, or an NIHSS score \<=1, at 7 days after treatment.

    Time frame: 7 days after treatment

  5. Change From Baseline in NIHSS Score at 24 Hours

    Change in NIHSS score from baseline at 24 hours after treatment.

    Time frame: Baseline and 24 hours after treatment

  6. Change From Baseline in NIHSS Score at Day 7

    Change in NIHSS score from baseline at 7 days after treatment.

    Time frame: Baseline and 7 days after treatment

  7. Proportion of Participants With a Barthel Index of 95-100

    Proportion of participants with a Barthel Index score of 95-100 at 90 days after treatment.

    Time frame: 90 days after treatment

  8. Proportion of Participants Achieving Reperfusion at 24 Hours

    Proportion of participants achieving reperfusion at 24 hours after treatment, defined as a \>90% reduction from baseline in the volume of tissue with tracer arrival time (Tmax) \>6 seconds.

    Time frame: 24 hours after treatment

  9. Proportion of Participants Achieving Good Reperfusion on Angiography Before Thrombectomy

    Proportion of participants achieving good reperfusion, defined as an expanded Thrombolysis in Cerebral Infarction (eTICI) grade of 2b50 or higher, on angiography before thrombectomy (assessed only in participants undergoing mechanical thrombectomy).

    Time frame: Before mechanical thrombectomy (Day 0)

  10. Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the SITS-MOST Definition

    Incidence of symptomatic intracranial hemorrhage as defined by the SITS-MOST criteria.

    Time frame: Within 36 hours after treatment

  11. Incidence of Symptomatic Intracranial Hemorrhage (sICH) per the ECASS III Definition

    Incidence of symptomatic intracranial hemorrhage as defined by the ECASS III criteria.

    Time frame: Within 7 days after treatment

  12. Incidence of All-Cause Mortality Within 7 Days

    Incidence of death from any cause within 7 days after treatment.

    Time frame: Within 7 days after treatment

  13. Incidence of All-Cause Mortality Within 90 Days

    Time frame: Within 90 days after treatment

  14. Incidence of Major Bleeding Events Within 7 Days

    Time frame: Within 7 days after treatment

  15. Incidence of Intracranial Hemorrhage Events Within 7 Days

    Within 7 days after treatment

    Time frame: Within 7 days after treatment

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Mar 2029, 27 months later.

Of 165 phase 3 interventional studies under Ischemic Stroke, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 52. This study's planned 27 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Jun 1, 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07942584
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Mar 1, 2029 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Yongjun Wang, MD, PhD
Contact
Yongjunwang111@aliyun.com
+86 13911172565
Chunjuan Wang, MD, PhD
Contact
wangchunjuan@ncrcnd.org.cn
+86 18210100840

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion